This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 26.0 kDa. The protein migrates as 30-35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Human Kallikrein 6, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Kallikreins are a subgroup of serine proteases, enzymes capable of cleaving peptide bonds in proteins. In humans, tissue kallikrein-related peptidases (KLKs) encode a family of fifteen closely related serine proteases. Kallikreins are responsible for the co-ordination of various physiological functions including blood pressure, semen liquefaction and skin desquamation. Serine protease which exhibits a preference for Arg over Lys in the substrate P1 position and for Ser or Pro in the P2 position. Shows activity against amyloid precursor protein, myelin basic protein, gelatin, casein and extracellular matrix proteins such as fibronectin, laminin, vitronectin and collagen.
Kallikrein-6 (KLK6) is also known as Bssp, Klk7, MGC9355, PRSS18, PRSS9, SP59 and hK6. KLK6 is one of the fifteen kallikrein subfamily members, and is regulated by steroid hormones. In tissue culture, KLK6 has been found to generate amyloidogenic fragments from the amyloid precursor protein, suggesting a potential for involvement in Alzheimer's disease. The prior studies indicate KLK6 is elevated at sites of central nervous system (CNS) inflammation and which shows regulated expression with T cell activation. Notably, KLK6 is also elevated in the serum of multiple sclerosis (MS) patients. KLK6 promotes lymphocyte survival by a mechanism that depends in part on activation of PAR1. KLK6 are also associated with neuronal plasticity in the central nervous system.